Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[111In]In-DOTA-ZROR1 (also known as [111In]In-DOTA-ZROR1:A10) is a first-in-class radiolabeled affibody-based imaging agent designed for single-photon emission computed tomography (SPECT) visualization of tumor-associated receptor tyrosine kinase-like orphan receptor 1 (ROR1) expression. The agent consists of a high-affinity ROR1-targeting affibody molecule, ZROR1 (specifically the ZROR1:A10 clone), conjugated to the chelator DOTA and radiolabeled with the gamma-emitting radionuclide indium-111 ([111In]). ZROR1 binds with high affinity to both human and murine ROR1 (Kd of 4 nM and 2 nM, respectively). Preclinical evaluations in ROR1-expressing tumor models (such as MDA-MB-468 breast cancer xenografts) have demonstrated rapid blood clearance, high tumor-to-blood ratios, and specific, saturable tumor uptake, highlighting its potential as a noninvasive diagnostic tool for patient stratification and treatment monitoring in ROR1-targeted therapies.
| Indication | Highest phase | Status |
|---|---|---|
| breast cancer and precursor lesions | Preclinical | Active |
| colorectal cancer (CRC) and precursor lesions | Preclinical | Active |
| ovarian cancer and premalignant lesions | Preclinical | Active |
Every indication, with countries and timelines, is in the full profile.
| Market | Status | Year |
|---|---|---|
| United States | Not approved | — |
| European Union | Not approved | — |
| China | Not approved | — |
| Japan | Not approved | — |
Approved indications and other markets are in the full profile.
Lead indication: breast cancer and precursor lesions
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [111In]In-DOTA-ZROR1.
Work on [111In]In-DOTA-ZROR1? Claim this page to correct or add information. Claim this page